Short-acting beta2-agonists for chronic obstructive pulmonary disease
18 results
1 - 18
Short-acting beta2-agonists for chronic obstructive pulmonary disease 
Short‐acting beta2‐agonists for stable chronic obstructive pulmonary disease- Inhaled short‐acting beta2‐agonists versus ipratropium for acute exacerbations of chronic obstructive pulmonary disease
- Chronic obstructive pulmonary disease (COPD)
- Anticholinergic bronchodilators versus beta2‐sympathomimetic agents for acute exacerbations of chronic obstructive pulmonary disease
- Indacaterol, a once‐daily beta2‐agonist, versus twice‐daily beta2‐agonists or placebo for chronic obstructive pulmonary disease
- Long-acting beta2-agonists for poorly reversible chronic obstructive pulmonary disease: Cochrane systematic review
- Dual combination therapy versus long‐acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network meta‐analysis
- Beta2‐agonists for exercise‐induced asthma
- Combined corticosteroid and long‐acting beta2‐agonist in one inhaler versus inhaled corticosteroids alone for chronic obstructive pulmonary disease
- Once daily long‐acting beta2‐agonists and long‐acting muscarinic antagonists in a combined inhaler versus placebo for chronic obstructive pulmonary disease
- Combined aclidinium bromide and long‐acting beta2‐agonist for chronic obstructive pulmonary disease (COPD)
- Use of medication during pregnancy